- CAS 184475-35-2
- Purity 99%
Location:Home > Active Pharmaceutical Ingredients > Gefitinib
Quality products?make an important contribution to long-term revenue and profitability. Chinese Manufacturer supply Gefitinib 184475-35-2 in stock with high standard
1.What is the Gefitinib ?
The EGFR or ErbB1 inhibitor gefitinib (Iressa(R), AstraZeneca) was originally approved by the US FDA in 2003 under accelerated regulations for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) after progression on docetaxel- and platinum-based chemotherapy. AstraZeneca voluntarily withdrew gefitinib from the market in 2005, owing to failed verification of clinical benefit during post-approval studies. In July 2015, FDA reinstated the approval of gefitinib for a different group of patients (i.e., NSCLC patients with EGFR mutations). Other approved kinase inhibitors targeting the ErbB family, which includes ErbB1/EGFR, ErbB2/human epidermal growth factor receptor 2 (Her2), ErbB3/ Her3, and ErbB4/Her4, are erlotinib (Tarceva(R), OSI Pharm.), lapatinib (Tykerb(R), GlaxoSmithKline), vandetanib (Caprelsa(R), AstraZeneca), afatinib (Gilotrif(R), Boehringer Ingelheim) , and osimertinib (Tagrisso(R), AstraZeneca). All approved EGFR family inhibitors share a common quinazoline scaffold with the exception of osimertinib, which has a pyrimidinylphenylamine scaffold that resembles that of imatinib and nilotinib. Gefitinib and vandetanib adopt the type I binding mode with “DFG-in” and αC-helix “in” conformation, while erlotinib and lapatinib bind to“DFG-in”with the αC-helix adopting an “out” conformation. Afatinib and osimertinib are covalent inhibitors with an electrophilic enone moiety.
Gefitinib has been used : To study its effective use in endometrial cancer therapy Cell proliferation, cell cycle and apoptosis assays Cell viability assay and colony formation assay
-
-
199327-61-2
7-methoxy-6-(3-morpholinopropoxy)-3,4-dihydroquinazolin-4-one
-
-
367-21-5
3-chloro-4-fluorophenylamine
-
-
184475-35-2
gefitinib
| Conditions | Yield |
|---|---|
|
7-methoxy-6-(3-morpholinopropoxy)-3,4-dihydroquinazolin-4-one;
With
thionyl chloride; N,N-dimethyl-formamide;
for 1h;
Reflux;
3-chloro-4-fluorophenylamine;
In
isopropyl alcohol;
for 1h;
Reflux;
|
84%
|
|
With
potassium carbonate;
In
isopropyl alcohol;
at 80 - 85 ℃;
for 1h;
|
82%
|
|
7-methoxy-6-(3-morpholinopropoxy)-3,4-dihydroquinazolin-4-one;
With
thionyl chloride;
In
N,N-dimethyl-formamide;
for 2h;
Heating;
3-chloro-4-fluorophenylamine;
In
N,N-dimethyl-formamide;
at 100 ℃;
for 1h;
Further stages.;
|
73%
|
|
7-methoxy-6-(3-morpholinopropoxy)-3,4-dihydroquinazolin-4-one;
With
triethylamine; trichlorophosphate;
In
toluene;
at 5 - 70 ℃;
3-chloro-4-fluorophenylamine;
In
isopropyl alcohol; toluene;
at 70 ℃;
for 1h;
|
62.86%
|
|
7-methoxy-6-(3-morpholinopropoxy)-3,4-dihydroquinazolin-4-one;
With
thionyl chloride;
for 4h;
Reflux;
3-chloro-4-fluorophenylamine;
In
i-Amyl alcohol;
for 6h;
Reflux;
|
-
-
367-21-5
3-chloro-4-fluorophenylamine
-
-
N′-[2-cyano-5-methoxy-4-{3-(4-morpholinyl)propoxy}phenyl]-N,N-dimethylformamidine
-
-
184475-35-2
gefitinib
| Conditions | Yield |
|---|---|
|
With
acetic acid;
at 130 ℃;
for 3h;
Temperature;
|
78%
|
|
With
acetic acid;
In
5,5-dimethyl-1,3-cyclohexadiene;
at 135 ℃;
|
71.1%
|
|
With
acetic acid;
at 125 - 130 ℃;
for 3h;
|
70%
|
2.What is the CAS number for Gefitinib ?
The CAS number of Gefitinib is 184475-35-2.
More information of Gefitinib 184475-35-2 are:
|
CAS?Number |
184475-35-2 |
|
Density |
1.322 g/cm3 |
|
Melting Point |
119-120 °C |
|
Boiling Point |
586.8 °C at 760 mmHg |
|
Flash Point |
308.7 °C |
|
Vapor Pressure |
0mmHg at 25°C |
|
Refractive Index |
1.621 |
|
HS CODE |
29349990 |
|
PSA |
68.74000 |
|
LogP |
4.28650 |
|
Pka |
7.00±0.10(Predicted) |
3.What are another words for Gefitinib ?
Synonyms?for?Gefitinib 184475-35-2:N-(3-chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine;ZD1839;4-(3-Chloro-4-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline;Irressat;Gefitinib (JAN/USAN);4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-;ZD 1839;4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholinyl)propoxy]-;
4.What is the molecular formula of Gefitinib?
The chemical formula of ?Gefitinib is?C22H24ClFN4O3 which containing 22 Carbon atoms,24 Hydrogen atoms,1 Chlorine atoms,1 Fluorine atoms,4 Nitrogen atoms and 3 Oxygen atoms,and the molecular weight of??Gefitinib?is 446.909.
5.What is Gefitinib (184475-35-2) used for?
Gefitinib was introduced in Japan as a daily oral monotherapy for the treatment of inoperable or recurrent non-small cell lung cancers (NSCLC). This anilinoquinazoline derivative can be synthesized in 6 steps starting from 6,7-dimethoxyquinazolin-4(3H)-one by successive monodemethylationlacetylation of the 6-hydroxy-group followed by chlorination and reaction with 3-chloro-4-fluoroaniline, finally deacetylation and alkylation with 3-(4-morpholinyl)propylbromide complete the synthesis. Gefitinib reversibly inhibits the activity of the epidermal growth factor receptor tyrosine kinase (EGRF TK). This inhibits autophosphorylation of EGRF and blocks the cascade of intracellular events which have been implicated in the proliferation, survival and metastasis of cancer cells. Gefitinib diplays good selectivity for the EGRF TK relative to other growth factors in human umbilical endothelial cells. It is similarly selective relative to other kinases, for example cerB2. Data from two large phase II studies in patients with pretreated NSCLC have shown that gefitinib induces a response rate approaching 20% in patients receiving the agent as a second line therapy and approximately 10% in those pretreated with more lines of chemotherapy. Gefitinib has good bioavailability and is metabolized in the liver via the cytochrome P450 3A4 enzyme system with a mean elimination half life of 28 h. Gefitinib has been generally well tolerated in cancer patients with predominant side effects being acne-like skin-rash, diarrhea, nausea, vomiting and mild to moderate myelosuppression. .
InChI:InChI=1/C22H24ClFN4O3/c1-29-20-13-19-16(12-21(20)31-8-2-5-28-6-9-30-10-7-28)22(26-14-25-19)27-15-3-4-18(24)17(23)11-15/h3-4,11-14H,2,5-10H2,1H3,(H,25,26,27)
Relevant articles related to Gefitinib:
|
Article |
Source |
|
Synthesis of gefitinib from methyl 3-hydroxy-4-methoxy-benzoate |
Ming, Dong Li,You, Guang Zheng,Ji, Min , p. 673 - 678 (2007) |
|
Synthesis of [11C]Iressa as a new potential PET cancer imaging agent for epidermal growth factor receptor tyrosine kinase |
Wang, Ji-Quan,Gao, Mingzhang,Miller, Kathy D.,Sledge, George W.,Zheng, Qi-Huang , p. 4102 - 4106 (2006) |
6.Buy Gefitinib with the best price .
Shanghai Majin Pharmaceutical & Chemical Technology Co. Ltd is a quality supplier of Gefitinib. Our main goal is customer satisfaction. Contact us to negotiate the best price for your business on Gefitinib 184475-35-2.